OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call...
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a...
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences.
OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated...
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences.
OmniAb, Inc. (NASDAQ: OABI) today announced its Chief Executive Officer Matt Foehr will ring the opening bell of the Nasdaq Stock Market in a ceremony today at 9:30 a.m. Eastern time. He will be joined...
OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista...